17 material Form 8-K filings that 16 companies we cover made with the SEC in May 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Director George Lowell resigned from the board of directors effective May 12, 2023, after serving since 2008. The filing states he did not resign over any disagreement with the company, and he will remain on the Scientific Advisory Board as a liaison between that board and the Board. The filing names the registrant as BiondVax Pharmaceuticals Ltd.; the company and Mr. Lowell are still negotiating his compensation for the new roles.
Mr. Lowell submitted his board resignation on May 10, 2023, effective May 12, 2023
He had served as a Board member since 2008; the Board chairman, Mark Germain, thanked him for 15 years of service
Mr. Lowell will stay on the Scientific Advisory Board and become a liaison between it and the Board
Compensation for his continuing and new roles is still under discussion
Chemomab Therapeutics reported a first-quarter 2023 net loss of $8.8 million, up from $5.1 million a year earlier, driven mainly by higher research and development spending. Cash, cash equivalents and short-term deposits fell to $32.8 million at March 31, 2023, from $39.9 million at December 31, 2022, and the company said its estimated cash runway now extends through the first half of 2024.
Net loss was $8.8 million, or about $0.04 per share, versus $5.1 million, or about $0.02 per share, in the first quarter of 2022.
R&D expenses were $6.9 million versus $2.7 million a year earlier, primarily due to increased clinical and preclinical activities.
Cash, cash equivalents and short-term bank deposits were $32.8 million at March 31, 2023, compared with $39.9 million at December 31, 2022.
Estimated cash runway was extended through the first half of 2024; the CM-101 Phase 2 PSC trial top-line data are expected in the second half of 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.